A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine (AZA) or low - dose cytarabine (LDAC) is active in patients with FLT3 - ITD
mutated myeloid leukemias, according to a new study.
A combination of the FLT3 kinase inhibitor quizartinib with 5 - azacitidine or low - dose cytarabine is active in patients with FLT3 - ITD
mutated myeloid leukemias, according to a new study.
Not exact matches
Several factors newly discovered to be phosphorylated by GSK - 3 are also known to be
mutated in acute
myeloid leukemia, a condition in which aberrant splicing causes uncontrolled white blood cell proliferation.
A Case of Therapy - Related Acute
Myeloid Leukemia in a Patient With Heterozygous Mutations in the Ataxia Telangiectasia
Mutated Gene
Two genes were already recurrently
mutated in the 7 WGS cases: RUNX1, a known
myeloid tumor suppressor, and UMODL1, for which mutations were recently reported in multiple myeloma and ovarian cancer.
A leukemia - associated CD34 / CD123 / CD25 / CD99 + immunophenotype identifies FLT3 -
mutated clones in acute
myeloid leukemia